Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Genomic Research Center, |
RCV000625787 | SCV000746337 | likely pathogenic | Methylmalonic aciduria, cblA type | 2017-12-03 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV000625787 | SCV002216462 | uncertain significance | Methylmalonic aciduria, cblA type | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 222 of the MMAA protein (p.Arg222Gly). This variant is present in population databases (no rsID available, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with MMAA-related conditions. ClinVar contains an entry for this variant (Variation ID: 522648). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MMAA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV003258891 | SCV003986676 | uncertain significance | Inborn genetic diseases | 2023-05-24 | criteria provided, single submitter | clinical testing | The c.664A>G (p.R222G) alteration is located in exon 4 (coding exon 3) of the MMAA gene. This alteration results from a A to G substitution at nucleotide position 664, causing the arginine (R) at amino acid position 222 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |